PMC Buys Isochem’s Pharma Business

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France’s Isochem for an undisclosed sum.

The business comprises research, product and process development capabilities as well as pilot-scale and full plant-scale production of drug intermediates and APIs for major companies worldwide.

Isochem operates three sites at Gennevilliers, Pithiviers and Vert-le-Petit, all within a 60-mile radius of Paris and audited by the US Food and Drug Administration (FDA) as cGMP-compliant.

Going forward, the company will be known as PMC Isochem, operating as a wholly owned subsidiary of PMC Group France.

The acquisition follows the October purchase of Indian pharma Yegna Manojavam Drugs and Chemicals by PMC Group subsidiary, PMC YM-Pharma. The Indian company’s cGMP plant is claimed to be one of the largest fluoroquinolone drug manufacturing facilities in France.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.